Visfatin is a positive regulator of MCP-1 in human adipocytes in vitro and in mice in vivo

Obesity

Volumn 18, Issue 8, 2010, Pages 1486-1492

  Sommer, Grit ^a   Kralisch, Susan ^a   Kloting, Nora ^a   Kamprad, Manja ^b   Schrock, Kathleen ^c   Kratzsch, Jurgen ^a   Tonjes, Anke ^a   Lossner, Ulrike ^a   Bluher, Matthias ^a   Stumvoll, Michael ^a   Fasshauer, Mathias ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Institute of Clinical Immunology and Transfusion Medicine   (Germany)

^c Translational Center for Regenerative Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ADIPOCYTE; ADULT; AGED; ANIMAL; ARTICLE; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CELL CULTURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

ADIPOCYTES; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELLS, CULTURED; CHEMOKINE CCL2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UP-REGULATION;

MUS;

EID: 77955050794     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2009.462     Document Type: Article

References (25)

1. Sjöholm A, Nyström T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev 2006;22:4-10.
2. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-1119.
3. Samal B, Sun Y, Stearns G et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431-1437.
4. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-430.
5. Dahl TB, Yndestad A, Skjelland M et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007;115:972-980.
6. Moschen AR, Kaser A, Enrich B et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-1758.
7. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008;78:356-365.
8. Kim SR, Bae YH, Bae SK et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 2008;1783:886-895.
9. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf) 2007;67:796-800.
10. Fasshauer M, Klein J, Kralisch S et al. Monocyte chemoattractant protein 1 expression is stimulated by growth hormone and interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2004;317:598-604.
11. Kralisch S, Klein J, Lossner U et al. Isoproterenol stimulates monocyte chemoattractant protein-1 expression and secretion in 3T3-L1 adipocytes. Regul Pept 2006;135:12-16.
12. Fasshauer M, Klein J, Kriauciunas KM et al. Essential role of insulin receptor substrate 1 in differentiation of brown adipocytes. Mol Cell Biol 2001;21:319-329.
13. Ziegelmeier M, Bachmann A, Seeger J et al. Serum levels of adipokine retinol-binding protein-4 in relation to renal function. Diabetes Care 2007;30:2588-2592.
14. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004;95:858-866.
15. Gu L, Okada Y, Clinton SK et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998;2:275-281.
16. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003;100:7265-7270.
17. Sell H, Dietze-Schroeder D, Kaiser U, Eckel J. Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology 2006;147:2458-2467.
18. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991;88: 1121-1127.
19. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab 2005; 90:2282-2289.
20. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000;49:883-888.
21. Virkamäki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999;103:931-943.
22. Fasshauer M, Kralisch S, Klier M et al. Insulin resistance-inducing cytokines differentially regulate SOCS mRNA expression via growth factor-and Jak/Stat-signaling pathways in 3T3-L1 adipocytes. J Endocrinol 2004;181:129-138.
23. Körner A, Garten A, Blüher M et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007;92:4783-4791.
24. Retnakaran R, Youn BS, Liu Y et al. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol (Oxf) 2008;69:885-893.
25. Nüsken KD, Petrasch M, Rauh M et al. Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol. Nephrol Dial Transplant 2009;24:2832-2838.